白血病干细胞免疫表型在治疗急性髓系白血病方面的研究进展  

Review on the application of leukemic stem cells immunophenotyping in the therapy of acute myeloid leukemia

作　　者：李倩[1] 彭琪[2] 夏平方[1] 魏姗姗[1] 佘妙容[1] 

机构地区：[1]广东省人民医院广东省医学科学院血液科,广东广州510080 [2]广州新海医院内科

出　　处：《中国输血杂志》2015年第4期462-466,共5页Chinese Journal of Blood Transfusion

基　　金：国家自然科学基金(81370664);广东省科技计划项目(2013B021800188);广东省中医药管理局基金(20131103)

摘　　要：急性髓系白血病(AML)是一类严重致死性疾病,其复发或耐药的根源在于白血病干细胞(LSCs)的存在,故清除LSCs成为治疗AML的关键。近年来发现一些免疫表型在LSCs上特异表达或者高表达,而在正常造血干细胞(HSCs)上不表达或者低表达,这就为特异杀伤LSCs提供了靶点,因此,研究LSCs的免疫表型,有助于识别并杀伤LSCs,从而为彻底治愈白血病提供可能。本文针对近年来LSCs免疫表型在AML治疗及其预后方面的相关研究做一综述。Acute myeloid leukemia( AML) is a kind of malignant and fatal disease,which may cause relapse or drug resistance because of the existence of leukemic stem cells( LSCs). Thus,the key to curing AML relies on eliminating LSCs.In recent years,some phenotypes were found specifically or highly expressed on LSCs,but were not or lowly expressed on HSCs,which provided specific targets for killing LSCs and curing AML. A review was conducted on the recent advances of the application of LSCs immunophenotyping in the therapy and prognosis of AML.

关 键 词：急性髓系白血病 白血病干细胞 造血干细胞 免疫表型 靶向治疗 

分 类 号：R457.7[医药卫生—治疗学] R557[医药卫生—临床医学]